A Multicenter, Postmarketing Observational Study to Evaluate Safety Regarding Amyloid-Related Imaging Abnormalities and Their Management in Patients With Early Alzheimer's Disease and Treated With Lecanemab
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• All participants who are treated with lecanemab in routine clinical practice
Locations
Other Locations
Japan
Eisai trial site 2
RECRUITING
Hiroshima
Eisai trial site 3
RECRUITING
Kyoto
Eisai trial site 1
RECRUITING
Tokyo
Contact Information
Primary
Eisai Inquiry Service.
eisai-chiken_hotline@hhc.eisai.co.jp
Time Frame
Start Date: 2024-02-14
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 5000
Treatments
All Participants
Participants prescribed lecanemab by a physician in routine clinical practice (post-marketing surveillance) will be observed prospectively for up to a maximum of 156 weeks or to the time of discontinuation, whichever occurs first.
Related Therapeutic Areas
Sponsors
Leads: Eisai Co., Ltd.